Treatment‐free remission as a new goal in the management of chronic myeloid leukemia: Clinical and biological aspects

2024-9-1

Bruton tyrosine kinase inhibitor monotherapy in B‐cell lymphoma and risk of infection: A systematic review and meta‐analysis of randomized controlled trials

2024-9-1

Research on the mechanism of <i>HOPX‐HDAC2</i> interaction inducing differentiation blockage in acute myeloid leukemia

2024-9-1

Secondary acute myeloid leukemia and early infection are independent predictors of poor survival in acute myeloid leukemia treated with hypomethylating agents and venetoclax

2024-9-1

Combined targeting of Hedgehog/GLI1 and Wnt/β‐catenin pathways in mantle cell lymphoma

2024-8-29

Characteristics, outcomes and health care utilization of patients with acute myeloid leukemia aged 70 years or older: A single‐center retrospective analysis

2024-8-13

Efficacy of escalating therapy with brentuximab vedotin‐AVD in advanced stage Hodgkin lymphoma patients with positive interim positron emission tomography after ABVD

2024-8-12

Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real‐world clinical setting

2024-8-9

From trials to statistical insights: Bortezomib's story in childhood T‐cell lymphoid malignancies

2024-8-7

Clinical characteristics and outcome of early‐stage diffuse large B cell lymphoma of female genital track: A retrospective study of the Hellenic cooperative lymphoma group

2024-8-6

Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors—The MicroLinf Study

2024-8-5

Prognostic value of the “dynamic” R2‐ISS in patients with multiple myeloma undergoing anti‐CD38 antibody‐based triplet therapies

2024-8-3

Issue Information

2024-7-28

TET2 regulates extranodal NK/T cell lymphoma progression through regulation of DNA methylation

2024-7-1

Venetoclax combined with daunorubicin and cytarabine (2 + 6) in acute myeloid leukemia: Updated results of a phase II trial

2024-7-1

Prescription patterns of venetoclax in acute myeloid leukemia

2024-7-1

Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospital

2024-7-1

Correction to Staging FDG‐avidity in extranodal marginal zone lymphoma (EMZL) by disease location

2024-6-21

Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy

2024-6-14

Correction to Real‐life study on the use of response adapted therapy in patients with Hodgkin Lymphoma: Results from a multicenter experience

2024-6-11

Clonal dynamics of Richter transformation in chronic lymphocytic leukemia

2024-6-9

Safety and effectiveness of mogamulizumab in relapsed or refractory CC chemokine receptor 4‐positive peripheral T‐cell lymphoma and relapsed or refractory cutaneous T‐cell lymphoma: A post‐marketing surveillance in Japan

2024-6-7

Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib

2024-6-7

A real‐life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis

2024-6-2

Metabolic pathway‐based subtyping reveals distinct microenvironmental states associated with diffuse large B‐cell lymphoma outcomes

2024-5-31

Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trials

2024-5-31

Issue Information

2024-5-31

Prognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patients

2024-5-1

FLT3‐ITD regulation of the endoplasmic reticulum functions in acute myeloid leukemia

2024-5-1

Real‐world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL‐CLLEAR study

2024-5-1

A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia

2024-5-1

Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis

2024-4-29

Retraction

2024-4-29

Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus‐associated mantle cell lymphoma

2024-4-27

Real‐life study on the use of response adapted therapy in patients with Hodgkin Lymphoma: Results from a multicenter experience

2024-4-25

Erratum to reply to “successful early use of anti‐SARS‐CoV‐2 monoclonal neutralizing antibodies in SARS‐CoV‐2 infected hematological patients—A Czech multicenter experience”: A case series of SARS‐CoV‐2 Omicron infection and aggressive lymphoma in the Sotrovimab era

2024-4-25

Discovery Science highlights from the 17th International Conference on Malignant Lymphoma

2024-4-23

Future perspectives of radiation therapy for Hodgkin Lymphoma: Risk‐adapted, response‐adapted, and safer than before

2024-4-23

Outcomes after treating advanced mantle cell lymphoma in a low‐income group at a Latin American center: The role of outpatient hematopoietic stem cell transplantation

2024-4-12

Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first‐line treatment: A 15‐year follow‐up of patients with advanced follicular lymphoma in JCOG0203

2024-4-10

Novel monoclonal antibodies: A really specific therapy for light chain amyloidosis

2024-4-9

Issue Information

2024-4-2

The <i>RAS</i>‐signaling‐pathway‐mutation‐related prognosis in B‐cell acute lymphoblastic leukemia: A report from South China children's leukemia group

2024-4-2

The role of baseline 2‐[¹⁸F]‐FDG‐PET/CT metrics and radiomics features in predicting primary gastric lymphoma diagnosis

2024-3-1

Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in <i>t</i> (8;21) acute myeloid leukemia

2024-3-1

Texture analysis of 18F‐FDG PET/CT and CECT: Prediction of refractoriness of Hodgkin lymphoma with mediastinal bulk involvement

2024-3-1